Viking Therapeutics VKTX

Nasdaq · Pharmaceutical Preparations
$25.84−1.26%Nov 19 close · Databento
Every report since 2023 →

Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.

2 stories have a settled next close so far (2 on the Wire). The record starts speaking at three.

The numbers

fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento
Revenue$0
ROIC-83.1%
EPS, diluted$-3.19 −215.8%
Modern Valuation (EOD)
Market Cap—
Enterprise Value—
EV / True FCF—
EV / FCF—
EV / Gross Profit—
EV / EBIT—
EV / Sales—
P / E (GAAP)—
P / FCF—
P / Oper. CF—
P / Book—
Owner & Cash Yields
True FCF Yield—
FCF Yield—
Owner Earn. Yield—
Earnings Yield—
Shareholder Yield—
Buyback Yield—
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh—
EPS (diluted)$-3.19
Compounder & Returns
Rule of 40—
ROIC-83.1%
Cash ROIC (CROIC)—
GP / Assets—
ROE—
ROA—
Gross Margin—
Oper. Margin—
Net Margin—
FCF Margin—
True FCF Margin—
Quality & Dilution
Cash Conversion—
Accrual Ratio−11.3%
SBC % of FCF—
SBC % of Rev—
Reinvest. Rate—
Sales Growth Y/Y—
Sales 3Y CAGR—
EPS Growth Y/Y−215.8%
FCF Growth Y/Y—
FCF 3Y CAGR—
Share Change Y/Y+3.3%
Balance Sheet & Scale
Revenue (FY)$0
Gross Profit (FY)—
Oper. Income (FY)$-393.3M
GAAP Net Income—
True FCF (ex-SBC)—
Cash & Equiv$165.8M
Total Debt—
Net Cash (Debt)$165.8M
Net Cash % MCap—
Debt / FCF (yrs)—
Current Ratio9.33127.52M sh
Price & Technicals (EOD)
Perf Week−6.31%
Perf Month−2.05%
Perf Quarter−23.75%
Perf Half Y−15.78%
Perf YTD−18.64%
SMA 20 Dist−3.42%$26.76
SMA 50 Dist−10.19%$28.77
SMA 100 Dist−19.05%$31.92
Window High−38.67%$42.13
Window Low+6.73%$24.21
RSI (14) · Vol44.074%v
Unlocked SEC EDGAR Accounting Statements (USD)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (USD)FY2021FY2022FY2023FY2024FY2025YoY Δ4Y CAGRTrend
Income Statement
Research & Development (R&D)$45.0M$54.2M$63.8M$101.6M$345.0M+239.4%+66.4%
Total Operating Expenses$55.7M$70.4M$100.8M$150.9M$393.3M+160.6%+63.0%
Income Tax Expense$2,000$1,000$1,000$1,000$1,000+0.0%−15.9%
Diluted Shares77.2M76.8M94.3M109.0M112.7M+3.3%+9.9%
Balance Sheet
Cash & Equivalents$26.4M$36.6M$55.5M$26.7M$165.8M+521.6%+58.4%
Total Current Assets$210.5M$167.0M$367.2M$907.2M$715.6M−21.1%+35.8%
Total Assets$210.7M$168.5M$368.5M$908.3M$715.7M−21.2%+35.8%
Total Current Liabilities$8.8M$21.9M$19.1M$27.4M$76.7M+179.7%+71.9%
Total Liabilities$8.8M$23.2M$20.1M$28.0M$76.7M+173.4%+71.9%
Stockholders' Equity$201.9M$145.3M$348.4M$880.3M$639.1M−27.4%+33.4%
Net Cash / (Net Debt)$26.4M$36.6M$55.5M$26.7M$165.8M+521.6%+58.4%
Invested Capital$175.5M$108.7M$292.9M$853.6M$473.3M−44.6%+28.1%
Cash Flow & Capital Allocation
Stock-Based Compensation (SBC)$6.1M$8.7M$16.8M$29.7M$40.8M+37.4%+60.8%
Share Repurchases (Buybacks)—$6.8M——$6.8M—+0.0%

Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.

On the Wire

what VKTX did at the next close after each story
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.